California firm takes cannabinoid research personally

by Invesbrain Tuesday, July 18, 2017
Print This Article

California firm looks to Israel for personalized cannabinoid approach

The news magazine ISRAEL21c reports a U.S. biopharma company is teaming up with an Israeli counterpart to forward the use of cannabinoids in the field of personalized medicine.

California-based CURE Pharmaceutical recently signed a memorandum of understanding with Therapix Biosciences of Tel Aviv. The “research collaboration” will be done in conjunction with the eight hospitals and medical centres of Israel’s Assuta Medical Centers.

Therapix’s lead compound THX-TS01 is currently in phase 2 clinical trials to treat Tourette’s syndrome. It hopes to begin a Phase 1 clinical trial for another compound, THX-ULD01, for the treatment of mild cognitive impairment.

Both compounds employ an “FDA-approved synthetic THC.”

Therapix is also developing new cannabinoid delivery technologies including nasal and sublingual (under the tongue) methods.

(READ MORE)

CMAJ commentary argues for two-stream cannabis system

Arguing ‘recreational cannabis and cannabinoid-based drugs (including medical cannabis) are not equivalent,’ the authors of a commentary in the Canadian Medical Association Journal say Canada should continue with a separate medical cannabis stream after legalization.

In a report by EurekAlert!, Elizabeth Cairns and Dr. Melanie Kelly of Dalhousie University’s Department of Pharmacology, write that “(without) a program that supports medical use, patients may lose access to treatments that the Federal Court of Canada has deemed appropriate, which fosters safe and appropriate use."

The Task Force on Cannabis Legalization and Regulation also recommended a two-streamed system.
According to the EurekAlert! report, “the authors suggest that a medical stream for cannabis and cannabinoids would reduce risk to patients, provide incentives for research into the therapeutic effects of cannabinoids, and provide educational resources for health care practitioners on the latest advances in cannabinoid research.”

(READ MORE)

U.S.-German-Israeli deal links cancer diagnostics with cannabinoids

MMJ Reporter writes an American cannabinoid firm with an R&D foothold in Israel is teaming up with a German “world pioneer in cancer diagnostics.”

Cannabics Pharmaceuticals Inc. recently agreed to become “the exclusive international provider unit” of SIMFO GmbH’s Circulating Tumour Cell (CTC) diagnostics to people suffering with cancer and being treated with CBDs.

SIMFO previously initiated preclinical trials into CBDs and drug development with Cannabics’ cannabinoid formulations.

Cannabics’ R&D facility is “concentrated” in Israel.

(READ MORE)

Data on CBD analogue to be presented at neuroscience meeting

Stockhouse reports Califonia-based NEMUS Bioscience is set to present research on its CBD analogue at the Annual Meeting of the Society of Neuroscience this November.

The data, compiled by NEMUS’ R&D partner the University of Mississippi “will show the superiority of the NEMUS proprietary analogue of CBD, NB2222, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator.”

The firm will also present data on the anti-addictive potential of NB2222.

"We have been able to demonstrate that NB2222 was able to deliver analgesia comparable to morphine, which has been implicated in the current global opioid abuse epidemic. The research team then moved to the next step using a validated animal model of addiction to opioids to assess the anti-abuse potential of NB2222 as a therapeutic. We look forward to presenting the data this fall," said Dr. Kenneth Sufka, research professor with the National Center for Natural Products Research at UM.

(READ MORE)

‘Flaw’ Discovered in Ohio’s Marijuana Licensing Process

An Ohio state auditor found that two state employees could have had the ability to manipulate applicant scores in Ohio’s competitive medical marijuana licensing process. Some of the fiercest competition for a piece of the marijuana market in the entire country has been in Ohi...

How to find stocks that are financially solid

A strong balance sheet helps good stocks measure up. (Flickr) What are we looking for? Canadian stocks that show strong balance sheet characteristics The screen  If you were given the offer to buy out a company, you likely wouldn’t accept without first doing research – or...

On Pheno Safari with the Jungle Boys

When it comes to hunting exotic terps, these boys are after big game. In a world of Blue Dreams and mystery bag-seed Cookie phenos, one might think the art of massive 1,000 seed propagation efforts in search of all-star genetics was dead — but that couldn’t be further from ...

Getting Ready for the Fore20 Cup with Expert Joints

Check out Craig Ex aka The Expert of Expert Joints at the Squamish Valley Golf and Country Club as we get ready for the 3rd annual Fore20 Golf Tournament and Cannabis Cup coming up fast on August 19th. Craig gets the lowdown on Fore20 2018 from Chad, who helped organize it as th...

Massachusetts Gov: Marijuana Delivery is a ‘Safety Risk’

In some states, opponents of marijuana say they prefer delivery to retail dispensaries — because retail dispensaries cause crime. Studies say they don’t. In Massachusetts, Gov. Charlie Baker and prosecutors are opposing delivery for the same safety worries. Recreational mar...

Massachusetts Gov: Marijuana Delivery Is a ‘Safety Risk’

In some states, opponents of marijuana say they prefer delivery to retail dispensaries — because retail dispensaries cause crime. Studies say they don’t. In Massachusetts, Gov. Charlie Baker and prosecutors are opposing delivery for the same safety worries. Recreational mar...

Canopy Growth Corp. can make big money on international sales for 3-4 more years, GMP says

As the still unknown date for Canadian legalization draws nearer, GMP Securities analyst Martin Landry has turned part of his focus to Canopy Growth Corp’s (TSX:WEED) international prospects. On February 14, Canopy Growith Corp. reported its Q3, 2018 results. The company earne...

Recent Pullback in Commodities Is Likely Tied to Stock Correction

My January 27 message wrote about a bullish breakout in commodity prices to the highest level in two years. I took that as another sign that inflation pressures were starting to build. The weekly bars in Chart 1 show that bullish breakout taking place in the Bloomberg Commodity ...

8 Cannabis Creams for Treating Dry Winter Skin

Marijuana-infused lotions can help moisturize weathered skin and provide additional calming benefits. It’s winter time and that means the days are short, dark and cold, and your skin is in need of some extra TLC to help combat the dryness that arctic temperatures can bring. D...

8 Cannabis Creams for Treating Your Dry Winter Skin

Cannabis creams can help moisturize weathered skin and provide additional calming benefits. It’s winter time and that means the days are short, dark and cold, and your skin is in need of some extra TLC to help combat the dryness that arctic temperatures can bring. During this...